Alzamend Neuro, Inc.
ALZN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001677077
In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Alzamend Neuro, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 11 | 7 | −4 |
| Shares | 63.2K | 2.18K | −61.0K (−96.5%) |
| Value | $59.9K | $6.36K | −$53.6K (−89.4%) |
New holders (2)
Institutions that held Alzamend Neuro, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 902 | $2.63K | 0.00% |
| Tower Research Capital LLC (TRC) | 797 | $2.32K | 0.00% |
Sold out (6)
Institutions that held Alzamend Neuro, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Geode Capital Management, LLC | 39,152 | $37.1K |
| Truist Financial Corp | 15,498 | $14.7K |
| Barclays PLC | 4,375 | $4.15K |
| City State Bank | 4 | $4 |
| Morgan Stanley | 3 | $3 |
| Parallel Advisors, LLC | 3 | $3 |